<DOC>
	<DOCNO>NCT01892618</DOCNO>
	<brief_summary>The purpose study determine whether patient chronic lymphocytic leukaemia ( CLL ) benefit vaccination 13-valent conjugated pneumococcal vaccine , Prevenar13 , compare conventional 23-valent capsular polysaccharide vaccine term immune response .</brief_summary>
	<brief_title>Pneumococcal Vaccine Untreated CLL Patients</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Untreated CLL patient Rai stage ( 0 IV ) , early possible diagnosis , always therapy monoclonal antibody and/or chemotherapy Immunosuppressive therapy plan start within 1 month Other malignancy Corticosteroids immunosuppressive drug Previous allergic reaction vaccination past Neutropenia ( PMNs &lt; 500 cells/mm3 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>